title: Lipoprotein composition in the insulin-deficient non-acidotic phase of type I diabetic patients and early evolution after the start of insulin therapy.
abstract: Lipoproteins, including intermediate density lipoproteins and lipoprotein(a), and apolipoproteins A-I, B, C-II, C-III and E, were studied in 13 newly-diagnosed type I diabetic patients with severe insulinopenia without dehydration or acidosis. At baseline, the main finding was a significant increase in serum triglycerides due to raised triglyceride concentrations in all lipoproteins, particularly triglyceride-rich lipoproteins. Cholesterol concentrations were slightly increased in lipoproteins and led to a significant increase in serum cholesterol. Two days after the start of insulin therapy, lipoprotein profiles had normalized except for the LDL triglyceride contents, which remained significantly increased on the fifth day of treatment. No significant modifications were observed in lipoprotein(a), apolipoproteins A-I and E concentrations throughout the study. However, serum apolipoproteins B, C-II and C-III were increased at baseline and fell to normal levels 2 days after the start of insulin therapy. On the other hand, apolipoprotein C-II/C-III ratios in high and very low density lipoprotein, showed no significant differences at baseline compared with controls, suggesting that an apolipoprotein C-II deficiency or apolipoproteins Cs imbalance can be ruled out. In conclusion, significant lipoprotein abnormalities were observed in the insulin-deficient state of type I diabetes mellitus; insulin therapy normalizes the lipoprotein profile in two days, except for low density lipoprotein triglyceride contents which remain increased at the fifth day.
authors.affiliation: Endocrinology Section, Hospital Universitari, Germans Trias i Pujol, Badalona, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Reverter
authors.forename: M
authors.initials: M
authors.lastname: Sentí
authors.forename: J
authors.initials: J
authors.lastname: Rubiés-Prat
authors.forename: A
authors.initials: A
authors.lastname: Lucas
authors.forename: I
authors.initials: I
authors.lastname: Salinas
authors.forename: E
authors.initials: E
authors.lastname: Pizarro
authors.forename: J
authors.initials: J
authors.lastname: Pedro-Botet
authors.forename: A
authors.initials: A
authors.lastname: Sanmartí
mesh_terms: D000293:Adolescent; D000328:Adult; D001053:Apolipoproteins / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D017270:Lipoprotein(a) / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D053419:Lipoproteins, IDL; D008297:Male
chemical_list: D001053:Apolipoproteins; D007328:Insulin; D017270:Lipoprotein(a); D008074:Lipoproteins; D053419:Lipoproteins, IDL